超声造影肝脏影像报告和数据管理系统发展现状及临床应用进展

丁建民; 秦正义; 王芳

doi:10.3969/j.issn.1001-5256.2022.02.043

超声造影肝脏影像报告和数据管理系统发展现状及临床应用进展

DOI: 10.3969/j.issn.1001-5256.2022.02.043

丁建民^{1a, 2, ,},
秦正义^{1a, 2},
王芳^{1b, 2}

1a.
天津市第三中心医院超声科，天津 300170
1b.
天津市第三中心医院消化肝病科，天津 300170
2.
天津市重症疾病体外生命支持重点实验室，天津市人工细胞工程技术研究中心，天津市肝胆研究所，天津 300170

基金项目:

津市卫生健康委员会科技项目 (MS20017)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：丁建民负责拟定写作思路，撰写论文并最后定稿；秦正义参与撰写论文，收集文献；王芳参与修改论文。

详细信息

通信作者:
丁建民, djmzyn1982@sina.com

计量
- 文章访问数: 632
- HTML全文浏览量: 204
- PDF下载量: 58
- 被引次数: 0
出版历程
- 收稿日期: 2021-10-11
- 录用日期: 2021-11-12
- 出版日期: 2022-02-20

Development and clinical application of contrast enhanced ultrasound Liver Imaging Reporting and Data System

Jianmin DING^{1a, 2
, ,},
Zhengyi QIN^{1a, 2},
Fang WANG^{1b, 2}

1a.
Department of Ultrasound, Tianjin Third Central Hospital, Tianjin 300170, China
1b.
Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital, Tianjin 300170, China
2.
Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Institute of Hepatobiliary Disease, Tianjin 300170, China

Research funding:

Tianjin Health Science and Technology Project (MS20017)

More Information

Corresponding author: DING Jianmin, djmzyn1982@sina.com

摘要

摘要: 肝细胞癌(HCC)是我国乃至世界较为高发的恶性肿瘤，早期诊断及治疗是改善患者预后的关键。为了方便不同中心、不同专业医生间的沟通交流，美国放射学会于2016年发布第一版超声造影肝脏影像报告和数据管理系统(CEUS LI-RADS)，对肝脏影像术语、技术、解释、报告及数据收集进行规定，同时对不同肝脏局灶性病变进行HCC的风险分层，在临床应用中逐渐展露出优势。本文就CEUS LI-RADS的发展现状及临床应用进展进行综述，认为应用CEUS LI-RADS对HCC高危人群肝脏局灶性病变进行临床管理具有巨大的潜在价值，而且相信在不久的将来CEUS LI-RADS适用人群和适应证将会不断扩展，更好的服务于临床。
- 癌, 肝细胞 /
- 超声检查 /
- 数据库管理系统
Abstract: Hepatocellular carcinoma (HCC) is a malignant tumor with high incidence in China and the whole world, and early diagnosis and treatment are the key to improving the prognosis of patients. To facilitate the communication and cooperation between doctors of different centers and specialties, American College of Radiology issued the first edition of contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System (LI-RADS) in 2016 to standardize the technical terms, techniques, interpretation, reporting, and data collection for liver imaging and perform HCC risk stratification for different focal liver lesions. This article reviews the development and clinical application of CEUS LI-RADS and believes that the application of CEUS LI-RADS has a great potential value in the clinical management of focal liver lesions in the population at a high risk of HCC, and the applicable population and indications for CEUS LI-RADS will continue to expand in the near future, so as to provide better service to clinical practice.
- Carcinoma, Hepatocellular /
- Ultrasonography /
- Database Management Systems

HTML全文

表 1 不同时相划分和需要观察的内容

时相	时间	观察内容
动脉期	10~20 s开始30~45 s结束	APHE、早期廓清(＜60 s)
门静脉期	30~45 s开始120 s结束	晚期廓清、廓清程度
延迟期	120 s开始4~6 min结束	扫查全肝，观察是否有其他结节

下载: 导出CSV

参考文献(32)

[1]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[2]	ALTEKRUSE SF, MCGLYNN KA, REICHMAN ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005[J]. J Clin Oncol, 2009, 27(9): 1485-1491. DOI: 10.1200/JCO.2008.20.7753.
[3]	SINGAL AG, PILLAI A, TIRO J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: A meta-analysis[J]. PLoS Med, 2014, 11(4): e1001624. DOI: 10.1371/journal.pmed.1001624.
[4]	LOPEZ PM, VILLANUEVA A, LLOVET JM. Systematic review: Evidence-based management of hepatocellular carcinoma—an updated analysis of randomized controlled trials[J]. Aliment Pharmacol Ther, 2006, 23(11): 1535-1547. DOI: 10.1111/j.1365-2036.2006.02932.x.
[5]	HEIMBACH JK, KULIK LM, FINN RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1): 358-380. DOI: 10.1002/hep.29086.
[6]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019.
[7]	Chinese Journal of Hepatology, Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on multidisciplinary diagnosis and treatment of precancerous lesions of hepatocellular carcinoma (2020 edition)[J]. J Clin Hepatol, 2020, 36(3): 514-518. DOI: 10.3969/j.issn.1001-5256.2020.03.007. 《中华肝脏病杂志》编辑委员会, 中华医学会肝病学分会肝癌学组. 肝细胞癌癌前病变的诊断和治疗多学科专家共识(2020版)[J]. 临床肝胆病杂志, 2020, 36(3): 514-518. DOI: 10.3969/j.issn.1001-5256.2020.03.007.
[8]	KOKUDO N, HASEGAWA K, AKAHANE M, et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines)[J]. Hepatol Res, 2015, 45(2). DOI: 10.1111/hepr.12464.
[9]	National Health and Family Planning Commission of the People's Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma (V2017)[J]. J Clin Hepatol, 2017, 33(8): 1419-1431. DOI: 10.3969/j.issn.1001-5256.2017.08.003. 中华人民共和国国家卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版)[J]. 临床肝胆病杂志, 2017, 33(8): 1419-1431. DOI: 10.3969/j.issn.1001-5256.2017.08.003.
[10]	OMATA M, LESMANA LA, TATEISHI R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma[J]. Hepatol Int, 2010, 4(2): 439-474. DOI: 10.1007/s12072-010-9165-7.
[11]	American College of Radiology. CEUS LI-RADS v2017 Core[EB/OL]. http://www.acr.org/quality-safety/resources/CEUSLIRADS.
[12]	TERZI E, IAVARONE M, POMPILI M, et al. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1, 006 nodules[J]. J Hepatol, 2018, 68(3): 485-492. DOI: 10.1016/j.jhep.2017.11.007.
[13]	SCHELLHAAS B, BERNATIK T, BOHLE W, et al. Contrast-Enhanced Ultrasound Algorithms (CEUS-LIRADS/ESCULAP) for the noninvasive diagnosis of hepatocellular carcinoma - a prospective multicenter DEGUM study[J]. Ultraschall Med, 2021, 42(2): 178-186. DOI: 10.1055/a-1198-4874.
[14]	STROBEL D, JUNG EM, ZIESCH M, et al. Real-life assessment of standardized contrast-enhanced ultrasound (CEUS) and CEUS algorithms (CEUS LI-RADS^Ⓡ/ESCULAP) in hepatic nodules in cirrhotic patients-a prospective multicenter study[J]. Eur Radiol, 2021, 31(10): 7614-7625. DOI: 10.1007/s00330-021-07872-3.
[15]	WANG JY, FENG SY, XU JW, et al. Usefulness of the contrast-enhanced ultrasound liver imaging reporting and data system in diagnosing focal liver lesions by inexperienced radiologists[J]. J Ultrasound Med, 2020, 39(8): 1537-1546. DOI: 10.1002/jum.15242.
[16]	SCHELLHAAS B, PFEIFER L, KIELISCH C, et al. Interobserver agreement for Contrast-Enhanced Ultrasound (CEUS)-based standardized algorithms for the diagnosis of hepatocellular carcinoma in high-risk patients[J]. Ultraschall Med, 2018, 39(6): 667-674. DOI: 10.1055/a-0612-7887.
[17]	LI J, CHEN M, WANG ZJ, et al. Interobserver agreement for contrast-enhanced ultrasound of liver imaging reporting and data system: A systematic review and meta-analysis[J]. World J Clin Cases, 2020, 8(22): 5589-5602. DOI: 10.12998/wjcc.v8.i22.5589.
[18]	LI J, LING W, CHEN S, et al. The interreader agreement and validation of contrast-enhanced ultrasound liver imaging reporting and data system[J]. Eur J Radiol, 2019, 120: 108685. DOI: 10.1016/j.ejrad.2019.108685.
[19]	LI W, LI L, ZHUANG BW, et al. Inter-reader agreement of CEUS LI-RADS among radiologists with different levels of experience[J]. Eur Radiol, 2021, 31(9): 6758-6767. DOI: 10.1007/s00330-021-07777-1.
[20]	SHIN J, LEE S, BAE H, et al. Contrast-enhanced ultrasound liver imaging reporting and data system for diagnosing hepatocellular carcinoma: A meta-analysis[J]. Liver Int, 2020, 40(10): 2345-2352. DOI: 10.1111/liv.14617.
[21]	SCHELLHAAS B, GÖRTZ RS, PFEIFER L, et al. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS[J]. Eur J Gastroenterol Hepatol, 2017, 29(9): 1036-1044. DOI: 10.1097/MEG.0000000000000916.
[22]	HUANG JY, LI JW, LU Q, et al. Diagnostic accuracy of CEUS LI-RADS for the characterization of liver nodules 20 mm or smaller in patients at risk for hepatocellular carcinoma[J]. Radiology, 2020, 294(2): 329-339. DOI: 10.1148/radiol.2019191086.
[23]	TAN Z, TEOH WC, WONG KM, et al. Analysis of comparative performance of CEUS and CECT/MR LI-RADS classification: Can CEUS dichotomize LI-RADS indeterminate lesions on CT or MRI?[J]. Clin Imaging, 2020, 62: 63-68. DOI: 10.1016/j.clinimag.2020.02.002.
[24]	ZHENG W, LI Q, ZOU XB, et al. Evaluation of Contrast-enhanced US LI-RADS version 2017: Application on 2020 Liver Nodules in Patients with Hepatitis B Infection[J]. Radiology, 2020, 294(2): 299-307. DOI: 10.1148/radiol.2019190878.
[25]	MAKOYEVA A, KIM TK, JANG HJ, et al. Use of CEUS LI-RADS for the accurate diagnosis of nodules in patients at risk for hepatocellular carcinoma: A validation study[J]. Radiol Imaging Cancer, 2020, 2(2): e190014. DOI: 10.11152/mu-2887.
[26]	GHIUCHICI AM, DǍNILǍ M, POPESCU A, et al. Contrast-enhanced ultrasound algorithm (ACR CEUS LI-RADSv 2017)- a valuable tool for the noninvasive diagnosis of hepatocellular carcinoma in patients with chronic liver disease[J]. Med Ultrason, 2021, 23(4): 383-389. DOI: 10.11152/mu-2887.
[27]	DING J, LONG L, ZHANG X, et al. Contrast-enhanced ultrasound LI-RADS 2017: Comparison with CT/MRI LI-RADS[J]. Eur Radiol, 2021, 31(2): 847-854. DOI: 10.1007/s00330-020-07159-z.
[28]	DING JM, LONG L, ZHOU HY, et al. The predictive value of Liver Imaging Reporting and Data System with contrast-enhanced ultrasound (v2017) in the risk of hepatocellular carcinoma in high-risk population[J] Chin J Ultrasonography, 2020, 29(2): 138-142. DOI: 10.3760/cma.j.issn.1004-4477.2020.02.007. 丁建民, 龙磊, 周洪雨, 等. 超声造影肝脏影像报告与数据系统对高危人群肝细胞癌的风险预测[J]. 中华超声影像学杂志, 2020, 29(2): 138-142. DOI: 10.3760/cma.j.issn.1004-4477.2020.02.007.
[29]	SHIN J, LEE S, KIM YY, et al. Contrast-enhanced ultrasound Liver Imaging Reporting and Data System category M: A systematic review and meta-analysis[J]. Ultrasonography, 2022, 41(1): 74-82. DOI: 10.14366/usg.21011.
[30]	LI F, LI Q, LIU Y, et al. Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: The evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017[J]. Eur Radiol, 2020, 30(1): 461-470. DOI: 10.1007/s00330-019-06317-2.
[31]	DING J, QIN Z, ZHOU Y, et al. Impact of revision of the LR-M criteria on the diagnostic performance of contrast-enhanced ultrasound LI-RADS[J]. Ultrasound Med Biol, 2021, 47(12): 3403-3410. DOI: 10.1016/j.ultrasmedbio.2021.08.007.
[32]	LI J, YANG L, MA L, et al. Diagnostic Accuracy of Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) for differentiating between hepatocellular carcinoma and other hepatic malignancies in high-risk patients: A meta-analysis[J]. Ultraschall Med, 2021, 42(2): 187-193. DOI: 10.1055/a-1309-1568.